Serotonin and the heart

Annals of Medicine

Volumn 32, Issue 3, 2000, Pages 195-209

  Frishman, William H ^a   Grewall, Pam ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Cardiovascular disease; Hypertension; Ketanserin; Serotonin antagonism

Indexed keywords

ANGIOTENSIN; KETANSERIN; NITRIC OXIDE; NORADRENALIN; RECEPTOR SUBTYPE; RITANSERIN; SEROTONIN; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

CARDIOVASCULAR DISEASE; CONSTIPATION; DIARRHEA; FATIGUE; HEADACHE; HUMAN; HYPERTENSION; ORTHOSTATIC HYPOTENSION; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QT INTERVAL; REVIEW; SEROTONINERGIC SYSTEM; SIDE EFFECT; SLEEP DISORDER; VASOCONSTRICTION; VERTIGO; XEROSTOMIA;

EID: 0034100396     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853890008998827     Document Type: Review

References (134)

1. Frishman WH, Mosenkis A, Huberfeld S, Okin S. Serotonin and serotonin antagonism in cardiovascular disease. In: Frishman WH, Sonnenblick EH, eds: Cardiovascular pharmacotherapeutics. New York, NY: McGraw Hill: 639-75.
2. Hedner T, Persson B. Effects of a new serotonin antagonist, ketanserin, in experimental and clinical hypertension. Am J Hypertens 1988; 1: 317S-28S.
3. Houston D, Vanhoutte P. Serotonin and the vascular system: role in health and disease and implications for therapy. Drugs 1986; 31: 149-61.
4. Page IH. Serotonin (5-hydroxytryptamine). Physiol Rev 1954; 14: 563-88.
5. Frishman WH, Okin S, Huberfeld S. Serotonin antagonism in the treatment of systemic hypertension: the role of ketanserin. Med Clin North Am 1988; 72: 501-22.
6. Myers J, Mecca T, Webb R. Direct and sensitizing effects of serotonin agonist and antagonists on vascular smooth muscle. J Cardiovasc Pharmacol 1985; 7 (Suppl 7): S44-8.
7. Cohen R. Serotonin and the blood-vessel wall. J Hypertens 1986; 4 (Suppl 5): S116-8.
8. Frishman WH, Huberfeld S, Okin S, Wang YH, Kumar A, Shareef B. Serotonin and serotonin antagonism in cardiovascular and noncardiovascular disease. J Clin Pharmacol 1995; 35: 541-72.
9. Vanhoutte P, Luscher T. Serotonin and the blood vessel wall. J Hypertens 1986; 4 (Suppl 1): S-29-35.
10. Van Nueten J, Janssens W. Augmentation of vasoconstrictor responses to serotonin by acute and chronic factors: inhibition by ketanserin. J Hypertens 1986; 4 (Suppl 1): S55-9.
11. Yildiz O, Smith JR, Pardy RE. Serotonin and vasoconstrictor synergism. Life Sci 1998; 62: 1723-32.
12. Vanhoutte P. Serotonin and the blood vessel wall. J Hypertens 1986; 4 (Suppl 5): S112-5.
13. Vikenes K, Farstad M, Nordrehaug JE. Serotonin is associated with coronary artery disease and cardiac events. Circulation 1999; 100: 483-9.
14. Arinami T, Ohtsuki T, Yamakawa-Kobayashi K, Amemiya H, Fujiwara H, Kawata K, et al. A synergistic effect of serotonin transporter gene polymorphism and smoking in association with CHD. Thromb Haemost 1999; 81: 853-6.
15. Comings DE, MacMurray JP, Gonzalez N, Ferry L, Peters WR. Association of the serotonin transporter gene with serum cholesterol levels and heart disease. Mol Genet Metab 1999; 67: 248-53.
16. Hollenberg N. Serotonin and the peripheral circulation. J Hypertens 1986; 4 (Suppl 1): S23-7.
17. Janssen P. Pharmacology of potent and selective S2 serotonergic antagonists. J Cardiovasc Pharmacol 1985; 7 (Suppl 7): S2-11.
18. Wright L, Homans D, Laxson D, Dai X, Bache RJ. Effects of serotonin and thromboxane A2 on blood flow through moderately well developed coronary artery vessels. J Am Coll Cardiol 1992; 19: 687-93.
19. Van Nueten J. Serotonin and the blood vessel wall. J Cardiovasc Pharmacol 1985; 7 (Suppl 7): S49-51.
20. Tschudi MR, Luscher TF. Age and hypertension differently affect coronary contractions to endothelin-1, serotonin, and angiotensins. Circulation 1995; 91: 2415-22.
21. Doggrell SA. Increase in affinity and loss of 5-hydroxytryptamine 2A-receptor reserve for 5-hydroxytryptamine on the aorta of spontaneously hypertensive rats. J Auton Pharmacol 1995; 15: 371-7.
22. Benzuly KH, Padgett RC, Kaul S, Piegors DJ, Armstrong ML, Heistad DD. Functional improvement precedes structural regression of atherosclerosis. Circulation 1994; 89: 1810-8.
23. Heistad DD, Armstrong ML, Baumbach GL, Faraci FM. Sick vessel syndrome. Recovery of atherosclerotic and hypertensive vessels. Hypertension 1995; 26: 509-13.
24. Ustunes L, Yasa M, Kerry Z, Ozdemir N, Berkan T, Erhan Y, et al. Effect of verapamil on intimal thickening and vascular reactivity in the collared carotid artery of the rabbit. Br J Pharmacol 1996; 118: 1681-8.
25. Yokota Y, Imaizumi Y, Asano M, Matsuda T, Watanabe M. Endothelium-derived relaxing factor released by 5-HT: distinct from nitric oxide in basilar arteries of normotensive and hypertensive rats. Br J Pharmacol 1994; 113: 324-30.
26. Matsuda K, Lozinskaya I, Cox RH. Augmented contributions of voltage-gated Ca2+ channels to contractile responses in spontaneously hypertensive rat mesenteric arteries. Am J Hypertens 1997; 10: 1231-9.
27. Bell DR. Effect of chronic high pressure on transient and tonic vascular contractions to serotonin in hypertension. Am J Hypertens 1995; 8(4 Pt 1): 365-74.
28. Mandinov L, Kaufmann P, Maier W, Hess OM. Flow-dependent vasodilation in the coronary circulation: alterations in diseased states. Semin Interv Cardiol 1998; 3: 5-12.
29. Vanhoutte PM. Endothelial dysfunction and vascular disease. Verh K Acad Geneeskd Belg 1998; 60: 251-66.
30. Vanhoutte PM. Endothelial dysfunction and atherosclerosis. Eur Heart J 1997; 18 (Suppl E): E19-29.
31. Shimada T, Murakami Y, Hashimoto M, Ishibashi Y, Inoue S, Katoh H, et al. Impairment of serotonin-mediated nitric oxide release across the coronary bed in patients with coronary spastic angina. Am J Cardiol 1999; 83: 953-5.
32. Murakami Y, Shimada T, Ishinaga Y, Kinoshita Y, Kin H, Kitamura J, et al. Transcardiac 5-hydroxytryptamine release and impaired coronary endothelial function in patients with vasospastic angina. Clin Exp Pharmacol Physiol 1998; 25: 999-1003.
33. Murakami Y, Ishinaga Y, Sano K, Murakami R, Kinoshita Y, Kitamura J, et al. Increased serotonin release across the coronary bed during a nonischemic interval in patients with vasospastic angina. Clin Cardiol 1996; 19: 473-6.
34. Takeshita A. Endothelin-1 is not involved in serotonin-induced coronary spasm in a swine model. Cardiovasc Res 1995; 30: 193-9.
35. Stassen FR, Fazzi GE, Leenders PJ, Smits JF, De Mey JG. Coronary arterial hyperreactivity and mesenteric arterial hyporeactivity after myocardial infarction in the rat. J Cardiovasc Pharmacol 1997; 29: 780-8.
36. Mongiardo R, Finocchiaro ML, Beltrame J, Pristipino C, Lombardo A, Cianflone D, et al. Low incidence of serotonin-induced occlusive coronary artery spasm in patients with recent myocardial infarction. Am J Cardiol 1996; 78: 84-7.
37. Meyrelles SS, Bernardes CF, Modolo RP, Mill JG, Vasquez EC. Bezold-Jarisch reflex in myocardial infarcted rats. J Auton Nerv Syst 1997; 63: 144-52.
38. Breuer J, Meschig R, Breuer H, Arnold G. Effects of serotonin on the cardiopulmonary circulatory system with and without 5-HT2-receptor blockade by ketanserin. J Cardiovasc Pharmacol 1985; 7 (Suppl 7): S64-6.
39. Missouris CG, Cappucio FP, Varsamis E, Barron JL, Carr E, Markandu ND, et al. Serotonin and heart rate in hypertensive and normotensive subjects. Am Heart J 1998; 135: 838-43.
40. Belougne-Malfatti E, Aguejouf O, Doutremepuich F, Doutremepuich C. Actions of neurotransmitters: acetylcholine, serotonin, and adrenaline in an experimental arterial thrombosis induced by oxygen free radicals. Thromb Res 1997; 88: 435-9.
41. Takano S. Role of 5-hydroxytryptamine in platelet thrombus formation and mechanisms of inhibition of thrombus formation by 5-hydroxytryptamine2A antagonists in rabbits. Arch Int Pharmacodyn Ther 1995; 330: 297-308.
42. De Cree J, Leempoels J, De Cock W, Geukens H, Verhaegen H. The antihypertensive effects of a pure and selective serotonin receptor blocking agent (R 41 468) in elderly patients. Angiology 1982; 32: 132-44.
43. Baudouin-Legros M, Le Quan-Bui K, Guicheney P, Kamal L, Meyer P. Platelet serotonin in essential hypertension and in mental depression. J Cardiovasc Pharmacol 1985; 7 (Suppl 7): S12-4.
44. Mantero F, Rocco S, Opocher G, Armanini D, Boscaro M, D'Agostino D. Effect of ketanserin in primary aldosteronism. J Cardiovasc Pharmacol 1985; 7 (Suppl 7): S172-5.
45. Chalmers JP, Pilowsky PM, Minson JB, Kapoor V, Mills E, West MJ. Central serotonergic mechanisms in hypertension. Am J Hypertens 1988; 1: 79-83.
46. Vanhoutte P, ed. Serotonin and the cardiovascular system. New York, NY: Raven Press; 1985.
47. McCall RB, Clement ME. Role of serotonin1A and serotonin2 receptors in the central regulation of the cardiovascular system. Pharmacol Rev 1994; 46: 231-43.
48. Chaouche-Teyara K, Lacolley P, Challande P, Fournier B, Laurent S, Safar M, et al. Effects of clonidine and flesinoxan on blood pressure variability in conscious spontaneously hypertensive rats. J Cardiovasc Pharmacol 1997; 30: 241-4.
49. Hansson L, Petitet A. Review of studies with urapidil in elderly hypertensives. Blood Press 1995; Suppl 3: 21-5.
50. Lee JY, Hancock AA, Warner RB, Brune ME, Meyer MD, DeBernardis JF. Cardiovascular activity of A-74283, a 5-hydroxytryptamine 1A agent, in the spontaneously hypertensive rat. Pharmacology 1998; 56: 17-29.
51. Anderson IK, Martin GR, Ramage AG. Evidence that activation of 5-HT2 receptors in the forebrain of anaesthetized cats causes sympathoexcitation. Br J Pharmacol 1995; 116: 1751-6.
52. Yoshioka M. Effect of a novel 5-hydroxytryptamine3-antagonist, GR38032F, on the 5-hydroxytryptamine-induced increase in carotid sinus nerve activity in rats. J Pharmacol Exp Ther 1989; 250: 637-41.
53. Pilowsky PM, Minson JB, Arnolda LF, Chalmers JP. Brain serotonin and hypertension. In: Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, diagnosis, and management. 2nd edn. New York, NY: Raven Press; 1995: 775-87.
54. Veelken R, Sawin LL, DiBona GF. Epicardial serotonin receptors in circulatory control in conscious Spague-Dawley rats. Am J Physiol 1990; 258: H466-72.
55. Fagard R, Fiocchi R, Lijnen P, Staessen J, Moerman E, Schaepdryver A, et al. Haemodynamic and humoral responses to chronic ketanserin treatment in essential hypertension. Br Heart J 1984; 51: 149-56.
56. Gradin K, Pettersson A, Hedner T, Persson B. Chronic 5-HT2 receptor blockade with ritanserin does not reduce blood pressure in the spontaneously hypertensive rat. J Neural Trans 1985; 64: 145-9.
57. Arneklo-Nobin B, Nobin A, Owman C, Tornebrandt K. Serotonergic mechanism in isolated human peripheral arteries and veins. J Cardiovasc Pharmacol 1985; 7 (Suppl 7): S52-5.
58. deLeeuw P, Birkenhager W. Chronic effects of serotonin inhibition in hypertensive patients: hemodynamic and humoral findings. J Cardiovasc Pharmacol 1985; 7 (Suppl 7): S137-9.
59. Reimann I, Frolich J. Mechanism of antihypertensive action of ketanserin in man. BMJ 1983; 287: 381-3.
60. Wenting G, Woittiez A, Man Int'Veld A, Schalekamp A. 5-HT, alpha-adrenoreceptors, and blood pressure effects of ketanserin in essential hypertension and autonomic insufficiency. Hypertension 1984; 6: 100-9.
61. Hara H, Kitajima A, Shimada H, Tamao Y. Antithrombotic effect of MC1-9042, a new antiplatelet agent on experimental thrombosis models. Thromb Haemostas 1991; 66: 484-8.
62. Herbert JM, Bernat A, Barthelemy G, Dol F, Rinaldi M. Anti-thrombotic activity of SR 46349, a novel, potent and selective 5-HT2 receptor antagonist. Thromb Haemostas 1993; 69(3): 262-7.
63. Wilson HC, Coffman W, Killam A, Cohen ML. LY53857, a 5-HT2 receptor antagonist, delays occlusion and inhibits platelet aggregation in a rabbit model of carotid artery occlusion. Thromb Haemostas 1991; 66: 355-60.
64. Fagard R, Fiocchi R, Lijnen P, Staessen J, Amery A. Hemodynamic response to chronic ketanserin treatment in essential hypertension. J Cardiovasc Pharmacol 1985; 7 (Suppl 7): S128-9.
65. Gradin K, Pettersson A, Hedner T, Persson B. Antihypertensive effects of ketanserin in the spontaneously hypertensive rat: mode of action. J Cardiovasc Pharmacol 1985; 7 (Suppl 7): S110-11.
66. Gasic S, Eichler H, Korn A. Effect of ketanserin on phenylephrine-dependent changes in splanchnic hemodynamics and systemic blood pressure in healthy subjects. J Cardiovasc Pharmacol 1985; 7: 219-23.
67. BalaSubramanian H, Lee S, Mah SC. Differences in the acute and chronic antihypertensive mechanism of action of ketanserin in spontaneously hypertensive rats. J Pharmacol Exp Ther 1993; 264: 129-34.
68. Lauw G, van Brummelem P, Doorenbos C, van der Velde E, van Zwieten P. The acute and chronic antihypertensive effects of ketanserin cannot be explained by blockade of vascular serotonin type 2, receptor or (1-adrenergic receptors. Clin Pharmacol Ther 1991; 49: 377-84.
69. Nelson M, Coghlan J, Denton D, Mills E, Scoggins B, Spence C, et al. Serotonergic mechanisms and blood pressure in sheep. J Cardiovasc Pharmacol 1985; 7 (Suppl 7): S117-9.
70. Furukawa Y, Saegusa K, Ogiwara Y, Chiba S. Effects of ketanserin on the pacemaker activity and contractility in the isolated, blood perfused dog atrium. J Cardiovasc Pharmacol 1986; 8: 967-72.
71. Fernández M, Pizcueta P, García-Pagán JC, Feu F, Cirera I, Bosch J, et al. Effects of ritanserin, a selective and specific S2-serotonergic antagonist, on portal pressure and splanchnic hemodynamics in rats with long-term bile duct ligation. Hepatology 1993; 18: 389-93.
72. Hosie J, Stott DJ, Robertson JIS, Ball SG. Does acute serotonergic type 2 antagonism reduce blood pressure? Comparative effects of single doses of ritanserin and ketanserin in essential hypertension. J Cardiovasc Pharmacol 1987; 10 (Suppl 3): S86-8.
73. Naslund TC, Merrell WJ, Nadeau JH, Wood AJJ. α-adrenergic blockade makes minimal contribution to ketanserin's hypotensive effect. Clin Pharmacol Ther 1988; 44: 699-703.
74. McCall RB, Harris LT. Characterization of the central sympatho-inhibitory action of ketanserin. J Pharm Exp Ther 1987; 241: 736-40.
75. Reimann I, Ziegler G, Ludwig L, Frolich J. Central and autonomic nervous system side effects of ketanserin. Arzneimittelforschung 1986; 36 (II): 1681-4.
76. van Zwieten PA, Mathy MJ, Boddeke HWGM, Doods HN. Central hypertensive activity of ketanserin in cats. J Cardiovasc Pharmacol 1987; 10 (Suppl 3): S54-8.
77. Hoyer D, Vos P, Closse A, Palacios JM, Engel G, Davies H. [3H] ketanserin labels 5-HT2 and alpha 1-receptors in human brain cortex. J Cardiovasc Pharmacol 1987; 10 (Suppl 3): S48-50.
78. Berdeaux A, Edourad A, Samii K, Giudicelli JF. Ketanserin and the baroreceptor reflex in normotensive individuals. Eur J Clin Pharmacol 1987; 32: 27-33.
79. Wenting G, Man Int'Veld A, Woittiez A, Boomsma F, Schalekamp M. Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist. BMJ 1982; 284: 537-9.
80. Breckenridge A. Ketanserin - a new antihypertensive agent. J Hypertens 1986; 4 (Suppl 1): S13-6.
81. Ferrara L, Fasano M, Soro S, Rubba P, Iannuzzi A. Cardiovascular effects of ketanserin, a new antiserotonergic agent in the treatment of arterial hypertension. J Clin Pharmacol 1985; 25: 187-92.
82. Ichikawa Y, Yokoyama M, Akita H, Fukuzaki H. Constriction of a large coronary artery contributes to serotonin induced myocardial ischemia in the dog with pliable coronary stenosis. J Am Coll Cardiol 1989; 14 (2): 449-59.
83. Hedner T, Persson B. Ketanserin in combination with beta-adrenergic receptor blocking agents in the treatment of essential hypertension. Br J Clin Pharmacol 1984; 18: 765-71.
84. Cameron H, Ramsay L. Ketanserin in essential hypertension: a double-blind, placebo-controlled study. Postgrad Med J 1985; 61: 583-86.
85. Navis G, de Jong P, van der Hem G, de Zeeuw D. Renal effects of ketanserin in essential hypertension. J Hypertens 1986; 4 (Suppl 1): S95-8.
86. Amery A, Fagard R, Fiocchi R, Lijnen P, Staessen J, Vermylen J. Antihypertensive action and serotonin-induced platelet aggregation during long-term ketanserin treatment in hypertensive patients. J Cardiovasc Pharmacol 1984; 6: 182-5.
87. Persson B, Hedner T, Berglund G. Ketanserin in essential hypertension: effects during rest and exercise. Eur J Clin Pharmacol 1983; 25: 307-12.
88. Zehender M, Meinertz T, Hohnloser S, Geibel A, Hartung J, Seiler K-U, et al. Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin. Am J Cardiol 1989; 63: 826-32.
89. Zehender M, Meinertz T, Hohnloser S, Geibel A, Hartung J, Seiler K-U, et al. Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin. Clin Physiol Biochem 1990; 8 (Suppl 3): 90-100.
90. Schalekamp A, Woittiez A, Wenting G, van den Meiracker A, Man Int'Veld A. Ketanserin: haemodynamic effects and mechanism of action. J Hypertens 1986; 4 (Suppl 1): S7-12.
91. De Cree J, Leempoels J, Demoen B, Verhaegen H. Ketanserin and red blood cell sodium content in hypertension. J Cardiovasc Pharmacol 1985; 7 (Suppl 7): S41-3.
92. Radermacher P, Huet Y, Pluskwa F, Herigault R, Mal H, Teisseire B, et al. Comparison of ketanserin and sodium nitroprusside in patients with severe ARDS. Anesthesiology 1988; 68: 152-7.
93. Saman S, Thandroyen F, Opie L. Serotonin and the heart: effects of ketanserin on myocardial function, heart rate, and arrhythmias. J Cardiovasc Pharmacol 1985; 7 (Suppl 7): S70-5.
94. Furukawa Y, Saegusa K, Ogiwara Y, Chiba S. Effects of ketanserin on the pacemaker activity and contractility in the isolated, blood perfused dog atrium. J Cardiovasc Pharmacol 1986; 8: 967-72.
95. Grobecker H, Gessler I, Delius W, Dominiak P, Kees F. Effect of ketanserin on hemodynamics, plasma catecholamine concentrations and serotonin uptake by platelets in volunteers and patients with congestive heart failure. J Cardiovasc Pharm 1985; 7 (Suppl 7): S102-4.
96. Kamiya K, Venkatesh N, Singh B. Acute and chronic effects of ketanserin on the electrophysiologic properties of isolated rabbit ventricular myocardium: particular reference to repolarization. Am Heart J 1988; 115: 1222-8.
97. Zaza A, Malfatto G, Rosen MR. Electrophysiologic effects of ketanserin on canine Purkinje fibers, ventricular myocardium and the intact heart. J Pharm Exp Ther 1989; 250: 397-405.
98. Cameron HA, Waller PC, Ramsay LE. The effect of ketanserin on the QT interval. Br J Clin Pharmacol 1987; 23: 630P.
99. Nademanee K, Lockhart E, Pruitt C, Singh BN. Cardiac electro-physiologic effects of intravenous ketanserin in humans. J Cardiovasc Pharmacol 1987; 10 (Suppl 3): S81-5.
100. Prevention of Atherosclerotic Complications: controlled trial of ketanserin. Prevention of Atherosclerotic Complications with Ketanserin Trial Group. BMJ 1989; 298: 424-30.
101. Zannad F, Voisin P, Pointel J, Schmitt C, Freitag B, Stoltz J. Effects of ketanserin on platelet function and red cell filterability in hypertension and peripheral vascular disease. J Cardiovasc Pharmacol 1985; 7 (Suppl 7): S32-4.
102. Waal-Manning H, Brown S, Spears G, Simpson G. Clinical studies with ketanserin in hypertension. J Cardiovasc Pharmacol 1985; 7 (Suppl 7): S154-8.
103. De Clerck F, Jageneau A, Dom J. Hemorheological effects of ketanserin, a selective 5HT2-receptor antagonist, in aged, spontaneously hypertensive dogs. Arch Int Pharmacodyn 1982; 258: 100-15.
104. Kirch W, Ohnhaus E. Double-blind comparison of ketanserin with atenolol: antihypertensive activity and effect on platelet function. J Hypertens 1986; 4 (Suppl 1): S67-71.
105. Arnout J, Van Russelt M, Deckmyn H, Vermylen J, Fiocchi R, Lijnen P, et al. Platelet hypersensitivity to serotonin after prolonged ketanserin intake. J Cardiovasc Pharmacol 1985; 7 (Suppl 7): S20-2.
106. Gleerup G, Persson B, Hedner T, Winther K. Serotonin-induced platelet aggregation predicts the antihypertensive response to serotonin receptor antagonists. Eur J Clin Pharmacol 1993; 44: 121-5.
107. Hedner T, Persson B, Berglund G. Ketanserin, a novel 5-hydroxytryptamine antagonist: monotherapy in essential hypertension. Br J Clin Pharmacol 1983; 16: 121-5.
108. Ferrara L, Fasano M, Soro S. Metabolic aspects of antihypertensive treatment with ketanserin (letter). J Cardiovasc Pharmacol 1985; 7: 1007-8.
109. DeMartini A, Pezano R, Bernardier E, Torres J, Genta C, Scheijgrond H, et al. Multicenter study with ketanserin in essential hypertension: an Argentine experiment. J Cardiovasc Pharmacol 1987; 10 (Suppl 3): S125-37.
110. Ferrara L, Fasano M, Rubba P, Soro S, Marotta G, Mancini M. Study with the competitive 5-HT2 serotonergic antagonist ketanserin. J Cardiovasc Pharmacol 1985; 7 (Suppl 7): S159-60.
111. Zabludowski J, Zoccali C, Isles C, Murray G, Robertson J, Inglis G, et al. Effect of the 5-hydroxytryptamine type 2 receptor antagonist, ketanserin, on blood pressure, the reninangiotensin system and sympathoadrenal function in patients with essential hypertension. Br J Clin Pharmacol 1984; 17: 309-16.
112. Wing L, Chalmers J, West M, Bune A, Ayres B, Graham J. Effect of ketanserin on blood pressure and biochemical parameters in patients with essential hypertension. J Cardiovasc Pharmacol 1985; 7 (Suppl 7): S164-7.
113. Sheps S, Schirger A, Zachariah P, Fisher L, Spiekerman R, Araas F, et al. Comparison of ketanserin and metoprolol in the treatment of essential hypertension. Arch Intern Med 1987; 147: 291-6.
114. Hedner T, Persson B, Berglund G. A comparative and long-term evaluation of ketanserin in the treatment of essential hypertension. J Cardiovasc Pharmacol 1985; 7 (Suppl 7): S148-53.
115. Doyle AE. Age-related effects of 5HT2 antagonists. J Cardiovasc Pharmacol 1991; 17 (Suppl 5): S29-34.
116. McCormack PME, Cox JP, Marron J, Mee F, Atkias N, O'Brien E, et al. The anti-hypertensive efficacy of ketanserin in the elderly evaluated by ambulatory blood pressure measurement. J Hum Hypertens 1990; 4: 565-70.
117. Gould SE, Silas JH, Hosie J. Could the increased antihypertensive efficacy of ketanserin in the elderly be due to altered pharmacokinetics? Cardiovasc Drugs Ther 1990; 4: 88-92.
118. Staessen J, Fagard R, Riocchi R, Lijnen P, Rorive G, Amery A. Double-blind comparison of ketanserin with propranolol in hypertensive patients: interim report. J Cardiovasc Pharmacol 1985; 7 (Suppl 7): S140-7.
119. Malatino LS, Stancanelli B, Greco G, Polizzi G, Assogna G, Zanna C, et al. Comparison of ketanserin and enalapril in the treatment of mild to moderate essential hypertension. Cardiovasc Drug Ther 1990; 4: 123-6.
120. Hannedouche T, Fillastre JP, Mimran A, de Treglode D, Schardt F, Rosenthal T, et al. Ketanserin versus nifedipine in the treatment of essential hypertension in patients over 50 years old: an international multicenter trial. J Cardiovasc Pharmacol 1987; 10 (Suppl 3): S107-12.
121. Zin C, Copertari P, Landi E, San Martin C, Lopes M, Feruglio F, et al. Evaluation of a new antihypertensive agent ketanserin versus methyldopa in the treatment of essential hypertension in older patients: an international multicenter trial. J Cardiovasc Pharmacol 1987; 10 (Suppl 3): S113-8.
122. Palermo A, Mara G, Pizza N, Constantini C, del Rosso G, Assogna G, et al. Clinical experience with ketanserin in the treatment of hypertension. J Hypertens 1986; 4 (Suppl 1): S81-3.
123. Andren L, Svensson A, Dahlof B, Eggertsen R, Hansson L. Ketanserin in hypertension: early clinical evaluation and dose-finding study of a new 5HT2 receptor antagonist. Acta Med Scand 1983; 214: 125-30.
124. Singh NK, Goyal RK. New classes of antihypertensive drugs: therapeutic potentials. Clin Exp Hypertens 1999; 21: 137-43.
125. Watts SW. The development of enhanced arterial serotonergic hyperresponsiveness in mineralocorticoid hypertension. J Hypertens 1998; 16: 811-22.
126. Watts SW, Baez M, Webb RC. The 5-hydroxytryptamine2B receptor and 5-HT receptor signal transduction in mesenteric arteries from deoxycorticosterone acetate-salt hypertensive rats. J Pharmacol Exp Ther 1996; 277: 1103-13.
127. Watts SW, Fink GD. 5-HT2B receptor antagonist LY-272015 is antihypertensive in DOCA-salt-hypertensive rats. Am J Physiol 1999; 276(3 Pt 2): H944-52.
128. Steyn DW, Odendaal HJ. Randomised controlled trial of ketanserin and aspirin in prevention of pre-eclampsia. Lancet 1997; 350: 1267-71.
129. Okin S, Huberfeld SI, Frishman WH, Soberman J, Laifer L, Greenberg S, et al. Serotonergic blockade compared to beta-adrenergic blockade in systemic hypertension: a double-blind comparison of ketanserin to propranolol. J Clin Pharmacol 1988; 28: 1008-16.
130. Rosenthal J, Koehle W, Gruebel B, Fisher R. Moderate essential hypertension control: a double-blind crossover study between a serotonin antagonist and a post-synaptic alpha blocker. J Hypertens 1986; 4 (Suppl 1): S85-7.
131. Varga G, Kordas K, Burghardt B, Gacsalyi I, Szenasi G. Effect of deramciclane, a new 5-HT receptor antagonist, on cholecystokinin-induced changes in rat gastrointestinal function. Eur J Pharmacol 1999; 367: 315-23.
132. Kiendaum P, Braun M, Hohlfeld R, Weber AA, Sarbia M, Schror K. Antiatherosclerotic effects of oral naftidrofuryl in cholesterol-fed rabbits involve inhibition of neutrophil function. J Cardiovasc Pharmacol 1995; 25: 774-81.
133. Pakala R, Pakala R, Sheng WL, Benedict CR. Serotonin fails to induce proliferation of endothelial cells preloaded with eicosapentaenoic acid and docosahexaneoic acid. Atherosclerosis 1999; 145: 137-46.
134. Pakala R, Pakala R, Radcliffe JD, Benedict CR. Serotonin-induced endothelial cell proliferation is blocked by omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids 1999; 60: 115-23.